{"filing":{"accession_number":"0001654954-26-006614","cik":"0001131399","ticker":"GLAXF","company_name":"GSK plc","form":"6-K","filing_date":"2026-07-13","report_date":null,"primary_document":"a9768l.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1131399/000165495426006614/a9768l.htm"},"events":[{"id":17465,"run_id":15641,"accession_number":"0001654954-26-006614","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This is a press release announcing positive interim results from the AZUR-1 phase II trial of Jemperli (dostarlimab) in dMMR/MSI-H locally advanced rectal cancer. The disclosure reports that the trial met its primary objective of sustained clinical complete response at 12 months and indicates potential for the drug to eliminate the need for chemotherapy, radiation, and surgery in some patients. While this is a clinical milestone and regulatory development (the company plans to share data with health authorities for accelerated FDA review), it does not fit the discrete event categories of earnings_release, ma_activity, or other specific types. It is a material operational/strategic development for an oncology-focused biopharmaceutical company, as positive trial results and regulatory pathway advancement directly affect the commercial prospects and pipeline value of a key asset.","company_name":"GSK plc","ticker":"GLAXF","filing_date":"2026-07-13","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":15956,"accession_number":"0001654954-26-006614","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This is a press release announcing positive interim results from the AZUR-1 phase II trial of Jemperli (dostarlimab) in dMMR/MSI-H locally advanced rectal cancer. The disclosure reports that the trial met its primary objective of sustained clinical complete response at 12 months and indicates potential for the drug to eliminate the need for chemotherapy, radiation, and surgery in some patients. While this is a clinical milestone and regulatory development (the company plans to share data with health authorities for accelerated FDA review), it does not fit the discrete event categories of earnings_release, ma_activity, or other specific types. It is a material operational/strategic development for an oncology-focused biopharmaceutical company, as positive trial results and regulatory pathway advancement directly affect the commercial prospects and pipeline value of a key asset.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-13T11:16:09.781218+00:00","company_name":"GSK plc","ticker":"GLAXF","filing_date":"2026-07-13"}]}